AdaptHealth Q2 revenue falls 0.7% to $800.4 million; Adjusted EBITDA guidance cut
AdaptHealth reported second quarter 2025 net revenue of $800.4 million, down 0.7% from $806.0 million, and net income attributable to the company of $14.7 million, down from $19.4 million. The company lowered its full-year 2025 Adjusted EBITDA guidance to $642 million to $682 million from $662 million to $702 million, which matters to shareholders because both headline profit and the outlook weakened.
Key points
- Net revenue was $800.4 million versus $806.0 million a year earlier, a decrease of 0.7%.
- Adjusted EBITDA was $155.5 million versus $165.3 million, a decrease of 5.9%.
- Full-year 2025 Adjusted EBITDA guidance was lowered to $642 million to $682 million from $662 million to $702 million.
- Full-year 2025 net revenue guidance was narrowed to $3.18 billion to $3.26 billion from $3.15 billion to $3.29 billion; free cash flow guidance of $170 million to $190 million was unchanged.
The filing
Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.